The Dermatology Digest

DECEMBER 27, 2024

Johnson & Johnson has entered into an exclusive licensing agreement for the global development, manufacturing and commercialization of a STAT6 program for autoimmune and allergic diseases, including atopic dermatitis (AD), from Kaken Pharmaceutical. the venture capital organization of Johnson & Johnson.

Dermatitis 36

Dermatitis Portfolios Pharmaceutical Innovations 36

The Dermatology Digest

OCTOBER 28, 2024

The FDA is reviewing a supplemental New Drug Application (sNDA) for tapinarof cream, 1%, as a potential treatment for atopic dermatitis (AD) in adults and children two years of age and older, with Prescription Drug User Fee Act (PDUFA) action expected in the fourth quarter of calendar year 2024.

Portfolios 36

Portfolios Dermatitis Office Partnerships 36

The Dermatology Digest

MARCH 5, 2024

Pharmacokinetic (PK) data showed a half-life of approximately 75 days across doses tested and pharmacodynamic (PD) data showed, deep and sustained inhibition of key atopic dermatitis (AD) biomarkers pSTAT6 and TARC for ~3 months (longest follow-up available, with inhibition still ongoing at time of the data cut).

Injections 36

Injections Safety Sustainability Clinic 36